Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil Bhalla

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Cancer|April 8, 2017
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approachPrajwal Chaitanya Boddu, Hagop M Kantarjian, Farhad Ravandi, et al.
Haematologica|April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cellsYannan Jia, Lina Han, Cassandra L Ramage, et al.
Cancer Cell|June 13, 2023
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell LymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Blood|April 7, 2022
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemiaMehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, et al.
Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Oncogene|December 17, 2002
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cellsMei Huang, Jay F Dorsey, P K Epling-Burnette, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
The American Journal of Surgical Pathology|July 2, 2019
Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell NeoplasmNarittee Sukswai, Phyu P Aung, C Cameron Yin, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Cancer|April 8, 2017
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approachPrajwal Chaitanya Boddu, Hagop M Kantarjian, Farhad Ravandi, et al.
Haematologica|April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cellsYannan Jia, Lina Han, Cassandra L Ramage, et al.
Cancer Cell|June 13, 2023
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell LymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Blood|April 7, 2022
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemiaMehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, et al.
Cancer Cell|October 20, 2012
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomasXinwei Zhang, Xiaohong Zhao, Warren Fiskus, et al.
Oncogene|December 17, 2002
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cellsMei Huang, Jay F Dorsey, P K Epling-Burnette, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
The American Journal of Surgical Pathology|July 2, 2019
Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell NeoplasmNarittee Sukswai, Phyu P Aung, C Cameron Yin, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Pageof 16